Pulmonary embolism (PE) is a serious and costly disease for patients and healthcare
systems. Guidelines emphasise the importance of differentiating between patients who are …

Pulmonary embolism (PE) remains a major healthcare problem. PE presents with a variety
of non-specific symptoms, and confirmation of diagnosis involves the use of clinical risk …

Pulmonary embolism (PE) is a frequent, serious and multifactorial disease, the incidence of
which increases with advanced age. In the absence of pathognomonic clinical signs or …

Pulmonary embolism can be life threatening and difficult to diagnose as signs and
symptoms are not specific. European guidelines recommend stratification of pulmonary …

Pulmonary embolism (PE), which can develop as a consequence of deep vein thrombosis
(DVT), is a serious and potentially fatal venous thromboembolic event. Patients with PE are …

Background: Pulmonary embolism (PE) can be a life-threatening emergency. Accurate
diagnostic techniques and patient-specific management strategies are necessary to ensure …

The three most controversial and unsolved issues in the treatment of pulmonary embolism
(PE) are:(1) the role of thrombolysis,(2) the role of low molecular weight heparin and length …

Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent
significant morbidity and mortality. The mainstay of therapy has been vitamin‐K antagonist …

Background Physicians from many different specialties see patients suffering from acute
pulmonary embolism (PE), which has an incidence of 39–115 cases per 100 000 persons …

Pulmonary embolism, despite being common, often remains elusive as a diagnosis, and
clinical suspicion needs to remain high when seeing a patient with cardiopulmonary …